Zelira Therapeutics Limited (ZLD.AX)
AUD 0.38
(0.0%)
AUD 0.38
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 5.18 Million AUD | -84.71% |
| 2023 | 33.89 Million AUD | -10.11% |
| 2022 | 37.7 Million AUD | -4.23% |
| 2021 | 39.36 Million AUD | 9.99% |
| 2020 | 35.78 Million AUD | 918.11% |
| 2019 | 3.51 Million AUD | -44.33% |
| 2018 | 6.31 Million AUD | -20.75% |
| 2017 | 7.96 Million AUD | 9003.45% |
| 2016 | 87.51 Thousand AUD | -78.56% |
| 2015 | 408.26 Thousand AUD | -47.67% |
| 2014 | 780.16 Thousand AUD | -27.66% |
| 2013 | 1.07 Million AUD | -24.66% |
| 2012 | 1.43 Million AUD | 63.54% |
| 2011 | 875.29 Thousand AUD | 25.95% |
| 2010 | 694.95 Thousand AUD | -80.41% |
| 2009 | 3.54 Million AUD | 153.52% |
| 2008 | 1.39 Million AUD | -84.91% |
| 2007 | 9.27 Million AUD | -64.95% |
| 2006 | 26.45 Million AUD | 163.92% |
| 2005 | 10.02 Million AUD | 17.33% |
| 2004 | 8.54 Million AUD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q4 | 5.18 Million AUD | 0.0% |
| 2024 Q2 | 3.22 Million AUD | 0.0% |
| 2024 FY | 5.18 Million AUD | -84.71% |
| 2023 FY | 33.89 Million AUD | -10.11% |
| 2023 Q2 | 35 Million AUD | 0.0% |
| 2023 Q4 | 33.89 Million AUD | 0.0% |
| 2022 Q2 | 41.85 Million AUD | 0.0% |
| 2022 Q4 | 37.7 Million AUD | 0.0% |
| 2022 FY | 37.7 Million AUD | -4.23% |
| 2021 Q2 | 42.85 Million AUD | 0.0% |
| 2021 Q4 | 39.36 Million AUD | 0.0% |
| 2021 FY | 39.36 Million AUD | 9.99% |
| 2020 Q2 | 34.92 Million AUD | 0.0% |
| 2020 FY | 35.78 Million AUD | 918.11% |
| 2020 Q4 | 35.78 Million AUD | 0.0% |
| 2019 FY | 3.51 Million AUD | -44.33% |
| 2019 Q2 | 4.84 Million AUD | 0.0% |
| 2019 Q4 | 3.51 Million AUD | 0.0% |
| 2018 Q4 | 6.31 Million AUD | 0.0% |
| 2018 FY | 6.31 Million AUD | -20.75% |
| 2018 Q2 | 7.5 Million AUD | 0.0% |
| 2017 FY | 7.96 Million AUD | 9003.45% |
| 2017 Q4 | 7.96 Million AUD | 0.0% |
| 2017 Q2 | 3.9 Million AUD | 0.0% |
| 2016 Q4 | 87.51 Thousand AUD | 0.0% |
| 2016 FY | 87.51 Thousand AUD | -78.56% |
| 2016 Q2 | 418.34 Thousand AUD | 0.0% |
| 2015 Q4 | 408.26 Thousand AUD | 0.0% |
| 2015 FY | 408.26 Thousand AUD | -47.67% |
| 2014 Q4 | 780.16 Thousand AUD | 0.0% |
| 2014 FY | 780.16 Thousand AUD | -27.66% |
| 2013 Q4 | 1.07 Million AUD | 0.0% |
| 2013 FY | 1.07 Million AUD | -24.66% |
| 2012 FY | 1.43 Million AUD | 63.54% |
| 2012 Q4 | 1.43 Million AUD | 0.0% |
| 2011 Q4 | 875.29 Thousand AUD | 0.0% |
| 2011 FY | 875.29 Thousand AUD | 25.95% |
| 2010 Q4 | 694.95 Thousand AUD | 0.0% |
| 2010 FY | 694.95 Thousand AUD | -80.41% |
| 2009 Q4 | 3.54 Million AUD | 0.0% |
| 2009 FY | 3.54 Million AUD | 153.52% |
| 2008 FY | 1.39 Million AUD | -84.91% |
| 2008 Q4 | 1.39 Million AUD | 0.0% |
| 2007 FY | 9.27 Million AUD | -64.95% |
| 2007 Q4 | 9.27 Million AUD | 0.0% |
| 2006 FY | 26.45 Million AUD | 163.92% |
| 2006 Q4 | 26.45 Million AUD | 0.0% |
| 2005 FY | 10.02 Million AUD | 17.33% |
| 2005 Q4 | 10.02 Million AUD | 0.0% |
| 2004 FY | 8.54 Million AUD | 0.0% |
| 2004 Q4 | 8.54 Million AUD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AdAlta Limited | 5.57 Million AUD | 6.991% |
| Acrux Limited | 8.96 Million AUD | 42.169% |
| Amplia Therapeutics Limited | 14.84 Million AUD | 65.083% |
| Biome Australia Limited | 8.27 Million AUD | 37.374% |
| BTC Health Limited | 5.14 Million AUD | -0.672% |
| Chimeric Therapeutics Limited | 15.27 Million AUD | 66.062% |
| CSL Limited | 56.93 Billion AUD | 99.991% |
| Clarity Pharmaceuticals Ltd | 154.62 Million AUD | 96.648% |
| Clinuvel Pharmaceuticals Limited | 231.12 Million AUD | 97.757% |
| Noxopharm Limited | 6.78 Million AUD | 23.591% |
| PharmAust Limited | 11.12 Million AUD | 53.407% |
| Proteomics International Laboratories Limited | 10.87 Million AUD | 52.337% |
| Prescient Therapeutics Limited | 20.39 Million AUD | 74.582% |
| PYC Therapeutics Limited | 91.23 Million AUD | 94.319% |
| Race Oncology Limited | 20.22 Million AUD | 74.376% |
| Starpharma Holdings Limited | 36.81 Million AUD | 85.92% |
| EZZ Life Science Holdings Limited | 25.55 Million AUD | 79.714% |
| Botanix Pharmaceuticals Limited | 112.46 Million AUD | 95.391% |
| Memphasys Limited | 12.43 Million AUD | 58.3% |
| Nyrada Inc. | 5.9 Million AUD | 12.253% |
| Anatara Lifesciences Ltd | 1.67 Million AUD | -210.12% |
| Telix Pharmaceuticals Limited | 398.3 Million AUD | 98.699% |
| Bio-Gene Technology Limited | 3.15 Million AUD | -64.053% |
| Patrys Limited | 4.16 Million AUD | -24.554% |
| Dimerix Limited | 32.07 Million AUD | 83.841% |
| Neuren Pharmaceuticals Limited | 247.97 Million AUD | 97.91% |
| Orthocell Limited | 26.61 Million AUD | 80.525% |
| Imugene Limited | 151.39 Million AUD | 96.576% |
| Cynata Therapeutics Limited | 8.38 Million AUD | 38.207% |
| Immutep Limited | 147.44 Million AUD | 96.485% |
| Arovella Therapeutics Limited | 13.28 Million AUD | 60.982% |
| Alterity Therapeutics Limited | 19.22 Million AUD | 73.036% |
| Nanollose Limited | 241.95 Thousand AUD | -2042.342% |
| Invex Therapeutics Ltd | 6.12 Million AUD | 15.304% |
| NeuroScientific Biopharmaceuticals Limited | 5.43 Million AUD | 4.644% |
| Island Pharmaceuticals Limited | 2.56 Million AUD | -102.124% |
| Biotron Limited | 493.47 Thousand AUD | -950.389% |
| Radiopharm Theranostics Limited | 72.03 Million AUD | 92.804% |
| Tissue Repair Ltd | 19.38 Million AUD | 73.267% |
| AnteoTech Limited | 9.38 Million AUD | 44.747% |
| Hexima Limited | 2.26 Million AUD | -128.445% |
| Paradigm Biopharmaceuticals Limited | 27.39 Million AUD | 81.076% |
| Recce Pharmaceuticals Ltd | 6.36 Million AUD | 18.623% |
| Avecho Biotechnology Limited | 7.31 Million AUD | 29.182% |
| Actinogen Medical Limited | 21.31 Million AUD | 75.678% |
| Immuron Limited | 15.54 Million AUD | 66.666% |
| Argenica Therapeutics Limited | 16.37 Million AUD | 68.35% |